Analysts at Canaccord Genuity began coverage on shares of TELA Bio (NASDAQ:TELA) in a report issued on Tuesday, The Fly reports. The brokerage set a “buy” rating on the stock.

Separately, Piper Jaffray Companies began coverage on shares of TELA Bio in a report on Tuesday. They issued an “overweight” rating on the stock.

NASDAQ:TELA opened at $12.31 on Tuesday. TELA Bio has a 52 week low of $10.78 and a 52 week high of $15.05.

In other TELA Bio news, major shareholder Orbimed Advisors Llc acquired 384,615 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were purchased at an average cost of $12.09 per share, for a total transaction of $4,649,995.35. Also, Director Matt Zuga bought 86,121 shares of TELA Bio stock in a transaction dated Friday, November 8th. The shares were acquired at an average cost of $12.09 per share, for a total transaction of $1,041,202.89.

About TELA Bio

TELA Bio, Inc, a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. It offers reinforced tissue matrix products for a variety of reconstruction procedures, including hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.

See Also: What is the float in trading stocks?

The Fly

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.